Skip to main content

Publications

What type of publication do you want to show?

2024

Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.

Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232

DOI
10.1093/jac/dkae232
Journal article

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., . . . Else, L. (2024). A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.. Journal of pharmaceutical and biomedical analysis, 245, 116155. doi:10.1016/j.jpba.2024.116155

DOI
10.1016/j.jpba.2024.116155
Journal article

Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.

van der Wekken-Pas, L., Nassiwa, S., Malaba, T., Lamorde, M., Myer, L., Waitt, C., . . . Colbers, A. (2024). Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.. AIDS (London, England). doi:10.1097/qad.0000000000003852

DOI
10.1097/qad.0000000000003852
Journal article

2023

Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS

Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057

DOI
10.4155/bio-2023-0057
Journal article

Development, Validation and Application of an LC-MS/MS Method for Quantification of Favipiravir in Human Plasma

DOI
10.2139/ssrn.4400896
Preprint

2022

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2

DOI
10.1016/s1473-3099(22)00644-2
Journal article

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., . . . Khoo, S. (2022). 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. LANCET HIV, 9(8), E534-E543. doi:10.1016/S2352-3018(22)00173-4

DOI
10.1016/S2352-3018(22)00173-4
Journal article

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2

DOI
10.1101/2022.07.20.22277797
Preprint

'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda

Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). 'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda. BMC PREGNANCY AND CHILDBIRTH, 22(1). doi:10.1186/s12884-022-04896-5

DOI
10.1186/s12884-022-04896-5
Journal article

<i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda

Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). <i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda. BMC WOMENS HEALTH, 22(1). doi:10.1186/s12905-022-01814-x

DOI
10.1186/s12905-022-01814-x
Journal article

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

Ochanda, P. N., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2022). A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00446-3

DOI
10.1186/s12981-022-00446-3
Journal article

Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199

DOI
10.1093/cid/ciac199
Journal article

Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in five randomised trials of 1074 pregnant women

Sokhela, S., Venter, F., Bosch, B., Akpomiemie, G., Tembo, A., Pepperrell, T., . . . Hill, A. (2022). Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in five randomised trials of 1074 pregnant women. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 25 (pp. 48-49). Retrieved from https://www.webofscience.com/

Conference Paper

Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants

Sokhela, S., Venter, F., Bosch, B., Akpomiemie, G., Tembo, A., Pepperrell, T., . . . Hill, A. (2022). Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 25 (pp. 19-20). Retrieved from https://www.webofscience.com/

Conference Paper

2021

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318

DOI
10.1093/jac/dkab318
Journal article

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

DOI
10.1101/2021.09.10.21263376
Preprint

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4

DOI
10.1186/s13063-021-05458-4
Journal article

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

DOI
10.1101/2021.05.03.21256309
Preprint

2020

Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda

Alhassan, Y., Twimukye, A., Malaba, T., Orrell, C., Myer, L., Waitt, C., . . . Taegtmeyer, M. (2020). Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda. BMC HEALTH SERVICES RESEARCH, 20(1). doi:10.1186/s12913-020-05580-0

DOI
10.1186/s12913-020-05580-0
Journal article

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

Griffiths, G., Fitzgerald, R., Jaki, T., Corkhill, A., Marwood, E., Reynolds, H., . . . Khoo, S. (2020). AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. TRIALS, 21(1). doi:10.1186/s13063-020-04473-1

DOI
10.1186/s13063-020-04473-1
Journal article

COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM

Perez Nicholas, O., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2020). COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM. In VALUE IN HEALTH Vol. 23 (pp. S184). Retrieved from https://www.webofscience.com/

Conference Paper

PIN90 COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM

Perez Nicholas, O., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2020). PIN90 COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM. Value in Health, 23, S184. doi:10.1016/j.jval.2020.04.553

DOI
10.1016/j.jval.2020.04.553
Journal article

2019

2018

Adjunctive rifampicin for <i>Staphylococcus aureus</i> bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Thwaites, G. E., Scarborough, M., Szubert, A., Nsutebu, E., Tilley, R., Greig, J., . . . Walker, A. S. (2018). Adjunctive rifampicin for <i>Staphylococcus aureus</i> bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. LANCET, 391(10121), 668-678. doi:10.1016/S0140-6736(17)32456-X

DOI
10.1016/S0140-6736(17)32456-X
Journal article

2015

Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir

Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376

DOI
10.1093/jac/dku376
Journal article

2014

The autonomous role of the research nurse

Reynolds, H., Harrison, J., Tamakalo, R., Hoyle, M. C., & Burgess, L. (2014). The autonomous role of the research nurse. HIV Nursing, 14(1), 12-16.

Journal article

2012

Accuracy of fluorodeoxyglucose positron emission tomography with computed tomography and magnetic resonance spectroscopy in differentiating between primary cerebral lymphoma and non- malignant CNS lesions in HIV infected patients

Hogan, C., Bonington, A., Bonington, S., Carrington, B., Julyan, P., Coutts, G., . . . Varma, A. (2012). Accuracy of fluorodeoxyglucose positron emission tomography with computed tomography and magnetic resonance spectroscopy in differentiating between primary cerebral lymphoma and non- malignant CNS lesions in HIV infected patients. In HIV MEDICINE Vol. 13 (pp. 33). Retrieved from https://www.webofscience.com/

Conference Paper

2011

Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology

Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.

Poster

2009

High risk of early failure of anti-retroviral therapy with Truvada/nevirapine and associated resistance mutations

Turtle, L., Reynolds, H., & Khoo, S. H. (2009). High risk of early failure of anti-retroviral therapy with Truvada/nevirapine and associated resistance mutations. In HIV MEDICINE Vol. 10 (pp. 19). Retrieved from https://www.webofscience.com/

Conference Paper

2004

The relationship between nevirapine plasma concentrations and abnormal liver function tests

Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS RESEARCH AND HUMAN RETROVIRUSES, 20(7), 716-722. doi:10.1089/0889222041524670

DOI
10.1089/0889222041524670
Journal article

2003

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring

Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/00002030-200305020-00029

DOI
10.1097/00002030-200305020-00029
Journal article

2002

Pharmacokinetics of saquinavir co-administered with cimetidine

Boffito, M., Carriero, P., Trentini, L., Raiteri, R., Bonora, S., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetics of saquinavir co-administered with cimetidine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(6), 1081-1084. doi:10.1093/jac/dkf232

DOI
10.1093/jac/dkf232
Journal article

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

Boffito, M., Arnaudo, I., Raiteri, R., Bonora, S., Sinicco, A., Di Garbo, A., . . . Di Perri, G. (2002). Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS, 16(15), 2081-2083. doi:10.1097/00002030-200210180-00015

DOI
10.1097/00002030-200210180-00015
Journal article

Simultaneous determination of rifampicin and efavirenz in plasma.

Boffito, M., Tija, J., Reynolds, H. E., Hoggard, P. G., Bonora, S., Di Perri, G., & Back, D. J. (2002). Simultaneous determination of rifampicin and efavirenz in plasma.. Therapeutic drug monitoring, 24(5), 670-674. doi:10.1097/00007691-200210000-00015

DOI
10.1097/00007691-200210000-00015
Journal article

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects

Boffito, M., Hoggard, P. G., Reynolds, H. E., Bonora, S., Meaden, E. R., Sinicco, A., . . . Back, D. J. (2002). The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 54(3), 262-268. doi:10.1046/j.1365-2125.2002.01663.x

DOI
10.1046/j.1365-2125.2002.01663.x
Journal article

Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting

Boffito, M., Bonora, S., Raiteri, R., Reynolds, H. E., Hoggard, P. G., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. THERAPEUTIC DRUG MONITORING, 24(4), 574-576. doi:10.1097/00007691-200208000-00021

DOI
10.1097/00007691-200208000-00021
Journal article

Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir

Clarke, S., Mulcahy, F., Bergin, C., Reynolds, H., Boyle, N., Barry, M., & Back, D. J. (2002). Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. CLINICAL INFECTIOUS DISEASES, 34(8), 1143-1145. doi:10.1086/339541

DOI
10.1086/339541
Journal article

Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment

Boffito, M., Rossati, A., Reynolds, H. E., Hoggard, P. G., Back, D. J., & Di Perri, G. (2002). Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS RESEARCH AND HUMAN RETROVIRUSES, 18(5), 341-342. doi:10.1089/088922202753519115

DOI
10.1089/088922202753519115
Journal article

Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354))

Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2002). Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354)). Journal of Antimicrobial Chemotherapy, 49(1), 227.

Journal article

Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir (vol 48, pg 351, 2001)

Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2002). Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir (vol 48, pg 351, 2001). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 49(1), 227. doi:10.1093/jac/49.1.227

DOI
10.1093/jac/49.1.227
Journal article

Simultaneous determination of rifampicin and efavirenz in plasma

Boffito, M., Tija, J., Reynolds, H. E., Hoggard, P. G., Bonora, S., Di Perri, G., & Back, D. J. (2002). Simultaneous determination of rifampicin and efavirenz in plasma. THERAPEUTIC DRUG MONITORING, 24(5), 670-674. doi:10.1097/00007691-200210000-00015

DOI
10.1097/00007691-200210000-00015
Journal article

2001

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. CLINICAL INFECTIOUS DISEASES, 33(9), 1595-1597. doi:10.1086/322519

DOI
10.1086/322519
Journal article

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Taylor, S., Reynolds, H., Sabin, C. A., Drake, S. M., White, D. J., Back, D. J., & Pillay, D. (2001). Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS, 15(15), 2051-2053. doi:10.1097/00002030-200110190-00022

DOI
10.1097/00002030-200110190-00022
Journal article

Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir

Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2001). Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 48(3), 351-354. doi:10.1093/jac/48.3.351

DOI
10.1093/jac/48.3.351
Journal article

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(3), 213-217. doi:10.1046/j.1365-2125.2001.00342.x

DOI
10.1046/j.1365-2125.2001.00342.x
Journal article

Therapeutic drug monitoring of anti-HIV drugs

Back, D. J., Khoo, S. H., Gibbons, S. E., Reynolds, H., Tjia, J. F., & Merry, C. (2001). Therapeutic drug monitoring of anti-HIV drugs. OPTIMAL DOSE IDENTIFICATION, 1220, 145-160. doi:10.1016/S0531-5131(01)00294-1

DOI
10.1016/S0531-5131(01)00294-1
Journal article

2000

A pharmacokinetic study of indinavir (IDV) 600 mg bd and ritonavir (RTV) 200 mg bd in plasma and semen of HIV-1 infected men

Taylor, S., Reynolds, H., Drake, S. M., Stradling, C., White, D. J., Gibbons, S. E., & Back, D. J. (2000). A pharmacokinetic study of indinavir (IDV) 600 mg bd and ritonavir (RTV) 200 mg bd in plasma and semen of HIV-1 infected men. In AIDS Vol. 14 (pp. S96). Retrieved from https://www.webofscience.com/

Conference Paper

The Liverpool Therapeutic Drug Monitoring Service - A summary of the service and examples of use in clinical practice

Gibbons, S. E., Reynolds, H. E., Tjia, J. F., Khoo, S. H., & Black, D. J. (2000). The Liverpool Therapeutic Drug Monitoring Service - A summary of the service and examples of use in clinical practice. In AIDS Vol. 14 (pp. S89-S90). Retrieved from https://www.webofscience.com/

Conference Paper

Therapeutic drug monitoring in the management of subjects an the protease inhibitors nelfinavir and saquinavir: Results of the Roche UK TDM Service

Gibbons, S. E., Reynolds, H. E., Tjia, J. F., Khoo, S. H., Drake, J., & Back, J. (2000). Therapeutic drug monitoring in the management of subjects an the protease inhibitors nelfinavir and saquinavir: Results of the Roche UK TDM Service. In AIDS Vol. 14 (pp. S89). Retrieved from https://www.webofscience.com/

Conference Paper